RAG1 and neoplasm: Although IgG responses specific for the tumour are generated after ingenol mebutate treatment of B16 tumours [21] (and T7 squamous cell carcinomas [9]), the Rag1-/- experiments would suggest such responses have minimal impact on relapse rates of the ingenol mebutate treated tumours.